Cm Management, LLC Atreca, Inc. Transaction History

Cm Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$0.88 - $1.22 $66,000 - $91,500	75,000 Added 27.27%	350,000 $343,000
Q4 2022 Feb 09, 2023	BUY	$0.78 - $1.68 $20,060 - $43,206	25,718 Added 10.32%	275,000 $220,000
Q3 2022 Nov 04, 2022	BUY	$1.59 - $2.74 $38,608 - $66,532	24,282 Added 10.79%	249,282 $391,000
Q2 2022 Aug 08, 2022	BUY	$1.56 - $3.25 $117,000 - $243,750	75,000 Added 50.0%	225,000 $403,000
Q1 2022 May 09, 2022	BUY	$1.61 - $5.2 $136,850 - $442,000	85,000 Added 130.77%	150,000 $476,000
Q4 2021 Feb 02, 2022	SELL	$2.87 - $6.29 $43,050 - $94,350	-15,000 Reduced 18.75%	65,000 $197,000
Q3 2021 Nov 08, 2021	BUY	$4.91 - $9.07 $98,200 - $181,400	20,000 Added 33.33%	80,000 $498,000
Q4 2020 Feb 04, 2021	BUY	$13.03 - $17.09 $781,800 - $1.03 Million	60,000 New	60,000 $969,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cm Management, LLC with notifications on news.